首页> 外文OA文献 >Correction to: Reflections on FDA Draft Guidance for Products Containing Nanomaterials: Is the Abbreviated New Drug Application (ANDA) a Suitable Pathway for Nanomedicines?

【2h】

Correction to: Reflections on FDA Draft Guidance for Products Containing Nanomaterials: Is the Abbreviated New Drug Application (ANDA) a Suitable Pathway for Nanomedicines?

机译：纠正：对含有纳米材料产品的FDA指导指南的思考：是缩写的新药申请（ANDA）纳米喂养ines的合适途径吗？

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Emily Marden; Ioanna Ntai; Scott Bass; Beat Flühmann;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
专利

1. An Assessment of Concerns Regarding New Regulatory Guidance for Combination Products: A Review of the Submissions Made to the FDA Regarding Their Proposed Draft New Guidance on Human Factors Studies for a Combination Product in an Abbreviated New Drug Application [J] . Lance Philip T., Greenaway Ruth V., Edwards Brian Therapeutic innovation & regulatory science. . 2019,第2期

机译：对新的联合产品的新监管指导的担忧评估：对FDA提交的审查关于其拟议的人类因素的新指南草案对缩写新药物申请中的组合产品的新指引
2. Regulatory considerations of pharmaceutical solid polymorphism in Abbreviated New Drug Applications (ANDAs). [J] . Raw AS, Furness MS, Gill DS, Advanced drug delivery reviews . 2004,第3期

机译：简明新药申请（ANDA）中药物固体多态性的法规考量。
3. Interchangeability Of Biological Drug Products-FDA Draft Guidance [J] . Endrenyi Laszlo, Markus Richard Journal of biopharmaceutical statistics . 2019,第6期

机译：生物药品制品的互换性 - FDA草案指导
4. Report of the AAPS Guidance Forum on the FDA Draft Guidance for Industry: Drug Products Including Biological Products that Contain Nanomaterials [O] . Jon S. B. de Vlieger, Daan J. A. Crommelin, Katherine Tyner, -1

机译：AAPS指导论坛关于FDA工业指导草案的报告：包含纳米材料的药物产品包括生物产品
5. Reflections on FDA Draft Guidance for Products Containing Nanomaterials: Is the Abbreviated New Drug Application (ANDA) a Suitable Pathway for Nanomedicines? [O] . Marden Emily, Ntai Ioanna, Bass Scott, 2018

机译：对含有纳米材料产品的FDA草案指南的思考：是缩写的新药申请（ANDA）纳米喂养的合适途径吗？
6. Guidance for FDA Staff and Industry: Marketed Unapproved Drugs. Compliance Policy Guide. Sec. 440.100 Marketed New Drugs Without Approved NDAs or ANDAs (September 19, 2011) [R] . 2011

机译：FDa工作人员和行业指南：未经批准的未经批准的药物。合规政策指南。秒。 440.100未经批准的NDa或aNDa上市的新药（2011年9月19日）

Correction to: Reflections on FDA Draft Guidance for Products Containing Nanomaterials: Is the Abbreviated New Drug Application (ANDA) a Suitable Pathway for Nanomedicines?

著录项

引文网络

相似文献

相关主题

期刊订阅